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Abstract
Aims: Lupus myocarditis occurs in 5–10% of patients with systemic lupus erythematosus 
(SLE). No single feature is diagnostic of lupus myocarditis. Speckle tracking 
echocardiography (STE) can detect subclinical left ventricular dysfunction in SLE patients, 
with limited research on its utility in clinical lupus myocarditis. We report on STE in 
comparison to conventional echocardiography in patients with clinical lupus myocarditis.
Methods and results: A retrospective study was done at a tertiary referral hospital in 
South Africa. SLE patients with lupus myocarditis were included and compared to healthy 
controls. Echocardiographic images were reanalyzed, including global longitudinal strain 
through STE. A poor echocardiographic outcome was defined as final left ventricular 
ejection fraction (LVEF) <40%. 28 SLE patients fulfilled the criteria. Global longitudinal 
strain correlated with global (LVEF: r = −0.808; P = 0.001) and regional (wall motion score: 
r = 0.715; P < 0.001) function. In patients presenting with a LVEF ≥50%, global longitudinal 
strain (P = 0.023), wall motion score (P = 0.005) and diastolic function (P = 0.004) were 
significantly impaired vs controls. Following treatment, LVEF (35–47% (P = 0.023)) and wall 
motion score (1.88–1.5 (P = 0.017)) improved but not global longitudinal strain. Initial LVEF 
(34%; P = 0.046) and global longitudinal strain (−9.5%; P = 0.095) were lower in patients 
with a final LVEF <40%.
Conclusions: This is the first known report on STE in a series of patients with clinical lupus 
myocarditis. Global longitudinal strain correlated with regional and global left ventricular 
function. Global longitudinal strain, wall motion score and diastolic parameters may be 
more sensitive markers of lupus myocarditis in patients presenting with a preserved LVEF 
≥50%. A poor initial LVEF and global longitudinal strain were associated with a persistent 
LVEF <40%. Echocardiography is a non-invasive tool with diagnostic and prognostic value 
in lupus myocarditis.
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Introduction
Lupus myocarditis is a serious manifestation of systemic 
lupus erythematosus (SLE) with clinically evident 
myocarditis occurring in 5–10% of patients (1, 2). No 
single clinical or imaging feature is diagnostic of lupus 
myocarditis. Although endomyocardial biopsy is regarded 
as the diagnostic gold standard, the invasiveness of the 
procedure and poor negative predictive value limit its 
utility (3). The diagnosis is usually based on a clinical 
impression of cardiac failure or unexplained arrhythmia, 
supported by non-invasive tests including cardiac 
imaging (4, 5).
Echocardiography is frequently used to support a 
diagnosis of lupus myocarditis (6, 7). Accurate assessment 
of ventricular wall motion (velocity) is essential in the 
evaluation of regional myocardial function. 
Cardiac magnetic resonance imaging is regarded as 
the non-invasive investigation of choice for the diagnosis 
of myocarditis, including lupus myocarditis (5, 8, 9). It is 
however an expensive tool especially in resource-limited 
settings. Echocardiography on the other hand is cost 
effective and can be utilized at the bedside, even in the 
unstable, ventilated patient.
The aim of our study was to give a comprehensive 
description of STE. Findings in comparison to 
conventional echocardiography, including tissue Doppler 
imaging in a group of patients with clinically evident 
lupus myocarditis and compare the results to that of a 
healthy control group.
Methods
Patients and controls
A retrospective study was done at Tygerberg Hospital, a 
tertiary referral center in the Western Cape of South Africa. 
Our institution renders a tertiary service to a population 
of approximately 3.6 million people in the Cape Town 
area. Clinical records of all SLE inpatients and outpatients 
between January 2008 and January 2014 were screened for 
inclusion. Adult (13  years and older) patients (fulfilling 
the 1997 revised American College of Rheumatology 
criteria) with a diagnosis of lupus myocarditis were 
included (10). Lupus myocarditis was defined as clinical 
and echocardiographic evidence of impaired myocardial 
function (regional and/or global) attributed to active SLE. 
Patients with a cardiomyopathy attributed to causes other 
than SLE were excluded. Controls were recruited from 
health care workers as well as medical students at our 
institution and matched to our patient group with regard 
to age, gender and ethnicity. All controls included were 
healthy, non-lupus individuals with no known cardiac 
risk factors or history of cardiovascular disease, a normal 
physical examination and a low pre-test probability of 
cardiac disease.
Clinical and laboratory data
Data collected included demographics (gender, age, 
ethnicity and co-morbid conditions); duration of SLE at 
diagnosis of lupus myocarditis; SLE Disease Activity Index 
(SLEDAI) at the time of diagnosis of lupus myocarditis; 
detail of systemic involvement; symptoms and signs 
of lupus myocarditis (11). Relevant laboratory data 
were documented including auto-antibody results and 
chemistry (serum-creatinine, cardiac enzymes and urine 
analysis). Chest radiographs, electrocardiograms and 
angiogram reports were included where available.
Conventional two-dimensional echocardiography and 
two-dimensional STE analysis
Standard two-dimensional echocardiograms were 
originally performed on all patients with a M4S probe 
using a Vivid 7 Dimension ultrasound system (General 
Electric Medical Systems, South Africa). All the available 
original echocardiographic images were retrieved form a 
digital image archive (EchoPAC platform (2DS-software 
package, version 3.3), General Electric Medical 
Systems) and reanalyzed by a clinician experienced in 
echocardiography. Serial images were described in relation 
to the time of lupus myocarditis diagnosis. Structural 
and functional measurements, including pulse wave and 
tissue Doppler imaging were done in accordance with 
international echocardiography guidelines (12, 13, 14). 
Global left ventricular function was obtained using the 
Simpsons biplane method or visual estimation if the 
endocardial definition was inadequate. Right ventricular 
function and hemodynamic changes were assessed by 
determining the tricuspid annular plane systolic excursion 
(TAPSE) and tricuspid regurgitation maximal velocity (TR 
Vmax) (15). Diastolic dysfunction was assessed in terms 
of mitral annular velocity in early diastole (MA E′ave) 
(average of lateral and septal measurement) as a marker 
of active, early left ventricular relaxation and the ratio of 
mitral peak velocity of early filling to early diastolic mitral 
annular velocity (MA E/E′) as marker of left ventricular 
filling pressures.
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Regional left ventricular function was described with 
regard to regional wall motion abnormalities based on 
the 16-segment model. The wall motion score index for 
an individual patient was derived as the sum of all scores 
divided by the number of segments visualized (13).
STE analysis was not included in the original 
echocardiographic assessment of the study population. 
Cine-loops that were stored in DICOM digital format were 
selected from three apical views (3-chamber, 4-chamber 
and 2-chamber views). The images were downloaded from 
a central archive to a computer workstation and analyzed 
offline using customized software within a personal 
computer workstation (EchoPAC platform). Longitudinal 
segmental strain was measured in the basal, mid and 
apical segments (according to the 17-segment model) 
while global peak longitudinal strain or peak systolic 
longitudinal strain rate was averaged from all 3 apical 
views. Only studies with images of sufficient quality were 
used for speckle tracking analysis. All controls underwent 
standard echocardiography, tissue Doppler imaging and 
STE analyses. Analyses were done in accordance with 
international guidelines (14, 16, 17, 18).
Outcomes
Follow-up was concluded on 31 October, 2014. Where 
follow-up echocardiograms were available, functional and 
structural parameters were described in terms of change 
from the time of diagnosis. A poor echocardiographic 
outcome was defined as a final left ventricular ejection 
fraction (LVEF) <40%.
Statistical analysis
Descriptive analysis was done using frequency tables 
with numerical variables summarized as means 
and a standard deviation with 95% confidence 
intervals (normally distributed) and median, range 
and interquartile range (not normally distributed). 
Comparisons between the patient and control group 
were made with the Fisher’s Exact Test (independent 
groups, binary), the Pearson chi-square test (various 
ethnic groups) and the independent samples test 
(normally distributed means).
The paired Wilcoxon signed-rank test (data not 
normally distributed) was used to compare the initial 
and final echocardiograms. The Mann–Whitney U test 
(data not normally distributed) was used to compare 
echocardiographic data in patients with a poor outcome to 
those without as well as in comparing echocardiographic 
data in patient with a preserved LVEF at diagnosis to 
those without.
Variables in the control group and the two different 
categories of LVEF were compared using the Kruskal–Wallis 
test (omnibus-). Dunnet’s post hoc test with adjustment 
for multiple testing was used to determine significant 
differences between the three groups.
Spearman’s correlations were used to determine 
the relationships among continuous variables 
(nonparametric, Spearman’s correlation coefficient) while 
Pearson two-tailed correlations were used to determine 
the relationships between global longitudinal strain 
and clinical parameters. A P < 0.05 was considered as 
statistically significant.
Ethical consideration
The study was approved by the Health Research Ethics 
Committee of Stellenbosch University, South Africa. 
Research was conducted according to the ethical 
guidelines and principles of the International Declaration 
of Helsinki, South African Guidelines for Good Clinical 
Practice and the Medical Research Council Ethical 
guidelines for research. In view of the retrospective nature 
of the study, the difficulty in tracing individual subjects 
and the absence of risk to the subjects, the Health Research 
Ethics Committee, Stellenbosch University granted a 
waiver of informed consent for the patients included into 
the study. Informed consent has been obtained from each 
healthy volunteer after full explanation of the purpose 
and nature of all procedures used.
Results
Clinical and demographic features
A total of 457 SLE patients’ clinical records were screened. 
Fifty-five patients were considered to have had possible 
lupus myocarditis of which 27 patients were excluded due 
to a cardiomyopathy attributed to causes other than SLE. 
Twenty-eight patients (6.1%) fulfilled inclusion criteria. 
Twenty-eight healthy non-lupus controls were included. 
There were no significant differences between the patient 
and control group with regard to gender, ethnicity and 
age. Details of the demographics, clinical and laboratory 
features of patients at the time of diagnosis are summarized 
in Table 1.
The anti-nuclear antibody titer was positive in all 
patients while antiphospholipid antibodies were present 
in two patients. Forty percent of patients had a raised 
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creatine kinase (median: 105 µg/L; interquartile range 
(IQR): 45–778) compared to a raised troponin-I (normal 
range <0.04 µg/L) in 72.7% (median: 0.109 µg/L; IQR: 
0.04–2.77). Although 67.9% of patients had concomitant 
lupus nephritis the median glomerular filtration rate was 
122 mL/min/1.73 m2 (IQR: 56–168).
Eighty-six per cent of patients presented with 
congestive cardiac failure while three patients (11%) 
presented in cardiogenic shock. The most frequent 
electrocardiogram findings were sinus tachycardia (75%) 
and non-specific ST segment and T-wave abnormalities 
(78%). Fourteen per cent of patients developed arrhythmias 
including ventricular extra systoles, atrial fibrillation and 
ventricular tachycardia. Chest radiographs had features 
of pulmonary congestion (78.6%) and pleural effusions 
(64.3%). One patient underwent angiography confirming 
normal coronary arteries.
Treatment of lupus myocarditis
The majority of patients were treated with corticosteroids 
including intravenous solu-medrol pulse therapy 
(67.9% of patients) and/or oral prednisone (96.4%). 
Further immunosuppressive therapy used as induction 
or maintenance therapy included cyclophosphamide, 
azathioprine, mycophenolate mofetil, intravenous 
immunoglobulin and rituximab. Four patients received 
more than one form of immunosuppression for either 
resistant lupus myocarditis or a relapse. Anti-failure 
therapy included angiotensin-converting enzyme 
inhibitors (71.4%), diuretics (75%), beta-blockers (60.7%) 
and inotropes (14.3%).
Echocardiographic features
Initial echocardiographic characteristics in patients 
compared to controls are summarized in Table  2. Left 
ventricular chamber size was preserved in 60.7% of 
patients at diagnosis. Seventeen patients (17/27; 63%) 
presented with a severely impaired LVEF (≤35%) while 
25.9% of patients had a normal to only mildly impaired 
LVEF (≥45%). In seven patients (36.8%), the median 
LVEF remained unchanged or deteriorated further despite 
treatment (Fig. 1).
Left ventricular filling pressures were normal (MA 
E/E′ <8) in 2/21 patients (9.5%) and increased (MA E/E′ 
Table 1 Demographic and clinical features of patients at the time of diagnosis of lupus myocarditis compared to a healthy 
non-lupus control group.
 Lupus myocarditis group Healthy control group
 n/total (%) n/total (%)
Female gender 26/28 (92.9) 26/28 (92.9)
Ethnicity: mixed racial ancestry 25/28 (89.3) 25/28 (89.3)
Age (years) mean ± s.d. 28.32 ± 11.35 28.48 ± 11.33
Duration of SLE (weeks) median (IQR) 11.5 (IQR: 0–119)  
SLEDAI median (IQR) 17.5 (IQR: 12.3–24)  
Lupus nephritis 19 (67.9)  
Co-morbidities   
Antiphospholipid syndrome 1/28 (3.6) 0/28 (0)
Hypertension 7/28 (25) 0/28 (0)
Diabetes mellitus 1/28 (3.6) 0/28 (0)
Dyslipidemia 2/28 (7.1) 0/28 (0)
Clinical features of lupus myocarditis   
Symptoms   
New York Heart Association class 3/more dyspnea 21/23 (91.3)  
Orthopnoea/paroxysmal nocturnal dyspnea 6/28 (21.4)  
Palpitations 1/28 (3.6)  
Chest pain 2/28 (7.1)  
Signs   
Respiratory crackles/pulmonary edema 24/28 (85.7)  
Pleural effusion 9/28 (32.1)  
Raised jugular venous pressure 7/28 (25)  
Displaced apex 8/28 (28.6)  
Tachycardia 26/28 (92.9)  
New murmur 1/28 (3.6)  
S3 gallop 11/28 (39.3)  
Pedal edema 12/28 (42.9)  
IQR, inter quartile range; s.d., standard deviation; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.
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>15) in 7/21 patients (33.3%). Left ventricular relaxation 
was impaired (MA E′ave <8 cm/s) in 11/23 patients 
(47.8%) (22). None of the control patients had evidence 
of impaired left ventricular relaxation or increased left 
ventricular filling pressures. Other parameters of regional 
and global left ventricular function (wall motion score 
and global longitudinal strain) were significantly reduced 
in comparison to the control group (P < 0.001).
At diagnosis, global longitudinal strain correlated well 
with other parameters of global left ventricular function 
(LVEF: r = −0.808; P = 0.001; Fig.  2A) and regional left 
ventricular function (wall motion score: r = 0.715; P < 0.001; 
Fig.  2B). No correlation was demonstrated between 
global longitudinal strain and parameters of diastolic left 
ventricular function (MA E/E′ (r = 0.205; P = 0.523); MA 
E′ave (r = −0.41; P = 0.165)) nor right ventricular function 
and – hemodynamics ((TAPSE): r = −0.039; P = 0.905; right 
ventricular systolic pressure (RSVP): r = 0.068; P = 0.841).
A weaker correlation was seen between global longi-
tudinal strain and renal function (glomerular  filtration 
rate: r = −0.502; P = 0.081). No other clinical parameters 
including age (r = −0.263; P = 0.386), SLEDAI (r = −0.277; 
P = 0.359) and duration of SLE (r = 0.304; P = 0.312), nor 
laboratory parameters (C-reactive protein, creatine kinase, 
troponin) showed any significant correlations with global 
longitudinal strain.
Echocardiographic features of patients with a preserved 
left ventricular function at diagnosis
Six patients (6/27) presented with a relatively preserved 
LVEF of ≥50%. In this subgroup of patients, other measures 
of left ventricular function including global longitudinal 
strain, wall motion score and measures of diastolic 
left ventricular function (MA E/E′ and MA E′ave) were 
significantly impaired in comparison to the control group 
while measures of right ventricular function (TAPSE) were 
not significantly different (Fig. 3A, B, C and D).
Follow-up data
Clinical follow-up data were available for a median period 
of 563 days (range 4–1740) after diagnosis. Although one 
patient was lost to follow-up, the latest available clinical 
detail (555  days since initial presentation) as well as a 
follow-up echocardiogram (283  days after presentation) 
were obtained from the patient’s medical records. At the 
Table 2 Echocardiographic findings of lupus myocarditis group at diagnosis (initial) compared to those of a healthy 
control group.
 Initial echocardiogram in lupus 
myocarditis group
Initial echocardiogram in healthy control 
group
 
 
Total n = 28 Median (IQR)/ratio (%) of test done Median (IQR)/ratio (%) of test done P value
Structural parameter    
LAa diameter (cm) 3.2 (2.8–3.9) 3.0 (2.8–3.3) 0.105
LVIDb (cm) 5.2 (4.4–5.6) 4.6 (4.3–4.8) 0.046
RVIDc (cm) 3.2 (2.7–3.7) 3.0 (2.9–3.2) 0.176
Valvular dysfunction (mild/moderate) 13/27 (48.2) MR 0/28 MR <0.001
 7/27 (25.9) TR 0/28 TR 0.007
Pericardial effusion Small 7/27 (25.9) All: 0/28 0.005
 Moderate: 2/27 (7.4)   
 Large: 1/27 (3.7)   
Regional function parameter
RWMA present 24/24 0/28  
Wall motion scored 2.0 (1.8–2.6) 1 (1–1) <0.001
Global function parameter
MA E′avee (cm/s) 8.0 (6.0–11.0) 12.0 (11.0–14.5) <0.001
MA E/E′f 11.6 (10.3–16.2) 7.3 (5.3–8.0) <0.001
LVEFg: numerical (%) 35 (26–46) 63.5 (58.0–68.0) <0.001
LVEF: categorical    
≥55% 2/27 (7.4) 28/28  
45–54% 5/27 (18.5)   
36–44% 3/27 (11.1)   
≤35% 17/27 (63.0)   
TAPSEh (cm) 1.7 (1.6–2.1) 2.0 (1.8–2.3) 0.006
GLSi (%) −10.9 (−13.7 to −7.8) −22.1 (−23.5 to −20.8) <0.001
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time, the patient had no clinical signs of lupus myocarditis 
and the LVEF had recovered to 45%.
Nineteen patients (67.9%) had one or more follow-up 
echocardiogram following the diagnosis of lupus 
myocarditis (median 390  days; IQR: 93–680). Repeat 
echocardiograms were not routinely done but requested 
at the discretion of the treating clinician. Of the nine 
patients who did not undergo follow-up imaging, seven 
died (three due to lupus myocarditis) while the remaining 
two patients showed a full clinical recovery without 
recurrence of cardiac manifestations (data available at 639 
and 750  days, respectively after their lupus myocarditis 
diagnosis).
Table 3 provides a detailed summary of the structural 
and functional echocardiographic findings of these 
19 patients at diagnosis as well as at follow-up (latest 
available echocardiogram). Following treatment for lupus 
myocarditis, both the median LVEF and wall motion 
score significantly improved (P = 0.023 and P = 0.017, 
respectively) in contrast to global longitudinal strain 
(P = 0.47) and parameters of diastolic function (MA E′ave: 
P = 0.649 and MA E/E′: P = 0.281).
Associations with a poor echocardiographic outcome
Following immunosuppressive therapy, five out of 19 
patients (26.3%) had a final LVEF <40%. A lower initial 
(at diagnosis) LVEF (P = 0.046) and global longitudinal 
strain (P = 0.095) were found in patients with a final LVEF 
of <40% compared to those patients where the LVEF 
recovered to ≥40% (Table 4).
Discussion
We have recently reported the clinical features and 
outcome of lupus myocarditis in the Western Cape, 
South Africa where we found a high mortality of 17.9% 
among our patients (19). To the best of our knowledge, 
this is the first report on the use of STE in a series of SLE 
patients with clinically evident lupus myocarditis. Our 
patients were predominantly young females with a recent 
onset of SLE and a high SLEDAI.
Huang and coworkers demonstrated the ability of STE 
to detect early impairment in left ventricular function 
in asymptomatic SLE patients (20). Abnormalities 
occurred in the absence of changes on conventional 
echocardiography and global longitudinal strain was 
independently associated with SLE disease activity. The 
relevance and clinical implications of these findings in 
asymptomatic SLE patients have not been clarified.
Echocardiographic findings
The majority of our patients (63%) presented with severe 
left ventricular dysfunction (LVEF ≤35%). Regional wall 
Figure 1
Flow chart depicting the improvement/
deterioration in left ventricular function (LVEF) 
from the time of diagnosis to the final 
echocardiogram in 19 patients where a follow-up 
echocardiogram was available. IQR, interquartile 
range; LVEF, left ventricular ejection fraction.
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motion abnormalities were present in all patients while 
global longitudinal strain was significantly impaired in 
comparison to the control group (P < 0.001). Parameters 
of diastolic function, left ventricular filling pressure 
and relaxation were impaired in 33.3% and 47.8% of 
patients, respectively.
It is well described that the subendocardial region 
is more sensitive to myocardial disease. Early loss of 
diastolic longitudinal relaxation (MA E′ave) is associated 
with elevated left ventricular filling pressures (MA E/E′) 
with predominantly diastolic dysfunction, while the LVEF 
may still be preserved. Diastolic function is often an early, 
sensitive marker of pathology in a variety of conditions 
affecting the left ventricle (16, 17, 21). Longitudinal strain 
or deformation, measured with STE, represents shortening 
of longitudinal myocardial fibers during systole, again 
an earlier, more sensitive marker of left ventricular 
dysfunction compared to LVEF (22). The midmyocardial 
and epicardial function may therefore remain relatively 
unaffected, with circumferential strain and twist showing 
compensation in order to preserve left ventricular systolic 
function (16).
We demonstrated a significant improvement in both 
the LVEF and wall motion score following treatment for 
myocarditis, in contrast to global longitudinal strain 
and diastolic parameters (MA E/E′ and MA E′), which 
did not improve significantly (Table 3).
Correlation between global longitudinal strain and  
other lupus myocarditis parameters
A strong correlation was demonstrated between global 
longitudinal strain and parameters of both global 
(LVEF) and regional (wall motion score) left ventricular 
function at the time of diagnosis. We did however not 
find a correlation between global longitudinal strain and 
parameters of diastolic function. The unexpected absence 
of a correlation between global longitudinal strain and 
these markers of early left ventricular dysfunction may be 
due to the relatively advanced left ventricular dysfunction 
found in the majority of our patients. This should be 
further explored in a larger cohort of SLE patients in the 
absence of clinical myocarditis or myocarditis with a 
relatively preserved systolic left ventricular function.
In contrast to the findings of Huang and coworkers, 
global longitudinal strain did not correlate with SLE disease 
activity (20). The patients from our study population did 
however present with significantly higher lupus activity 
(median SLEDAI of 17.5, IQR 2.3–24) in comparison to 
that of Huang’s study population (SLEDAI 10.5 ± 7.6). 
Whether this correlation between global longitudinal 
strain and lupus disease activity is only evident in patients 
without clinically evident lupus myocarditis or in patients 
with a lower disease activity can only be speculated.
We found a weak correlation between renal function 
and global longitudinal strain (r = −0.502; P = 0.081). 
Although 67.9% of our patients had concomitant lupus 
nephritis, this was of recent onset and in the absence 
of advanced renal dysfunction (median glomerular 
filtration rate 122 mL/min/1.73 m2 (IQR: 56–168)). Left 
ventricular dysfunction (uremic cardiomyopathy) is well 
described in end-stage renal disease (23). Impaired global 
longitudinal strain has been shown to be of diagnostic 
and prognostic value in this subset of patients (24). The 
Figure 2
Correlation between the median global longitudinal strain (%) and 
(A) median left ventricular ejection fraction (%) and (B) median wall 
motion score at diagnosis. GLS, global longitudinal strain; LVEF, left 
ventricular ejection fraction; WMS, wall motion score.
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possible correlation between mild, recent-onset renal 
impairment and left ventricular dysfunction, specifically 
abnormal global longitudinal strain has not previously 
been described and should be studied prospectively.
Lupus myocarditis in patients presenting with a 
preserved LVEF
Although severe left ventricular dysfunction (LVEF ≤35%) 
was found in 63% of patients, a significant proportion 
(22.2%) of patients presented with a relatively preserved 
LVEF of ≥50%. In patients with non-lupus myocarditis 
with a LVEF ≥50% on conventional echocardiogram, 
Hsiao and coworkers demonstrated significantly impaired 
global longitudinal strain in comparison to that of a 
healthy control group (25). Our results supported these 
findings with various other parameters of left ventricular 
function, including global longitudinal strain, wall 
motion score, MA E/E′ and MA E′ave being significantly 
impaired in this subgroup of patients compared to our 
control group.
Our findings also highlight the limitations of using 
the LVEF in isolation when assessing patients for possible 
myocarditis, in particular, before deterioration in left 
ventricular function.
Associations with a poor outcome
Out of 19 patients who had a follow-up echocardiogram, 
five had a poor echocardiographic outcome. We found a 
lower initial LVEF as well as global longitudinal strain in 
this subgroup of patients. An earlier diagnosis of lupus 
myocarditis, before significant left ventricular functional 
impairment occurs is likely to play a central role in an 
improved echocardiographic outcome.
Limitations
Our study had a retrospective design and we relied on the 
accuracy of clinical records. Despite the relatively small 
sample size, this is the largest reported series of patients 
with lupus myocarditis. Our patients were hospitalized, 
symptomatic SLE patients. The results would therefore 
not be applicable in asymptomatic SLE patients with 
possible subclinical myocardial dysfunction. None of 
our patients had histological confirmation of their 
myocarditis. We are therefore not able to exclude other 
causes of cardiomyopathy including undiagnosed 
antiphospholipid syndrome with microthrombosis or 
microvascular occlusion with 100% certainty. Patients 
included into the study had a known diagnosis of lupus 
Figure 3
Box and whisker plots show the comparison between patients who presented with either impaired (LVEF <50%) or preserved left ventricular systolic 
function (LVEF ≥50%) and normal controls by analysis of variance for GLS (A), WMS (B) and parameters of diastolic function, MA E/E′ (C) and MA E′ave 
(D). The numeric values reported denote the median (horizontal line of the box) and the inter quartile range (top and bottom line). E′, early diastolic 
mitral annular velocity, average of lateral and septal measurement; E/E′, ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular 
velocity (E′); GLS, global longitudinal strain; LM, lupus myocarditis; LVEF, left ventricular ejection fraction; MA, mitral annular; WMS, wall motion score.
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myocarditis, which could have led to expectation bias 
or diagnostic suspicion bias in the reanalysis of the 
echocardiographic data. 
Conclusion
STE is a non-invasive, cost effective tool with diagnostic 
and prognostic value in patients with clinically 
evident lupus myocarditis. At the time of diagnosis, 
we demonstrated strong correlations between STE 
(global longitudinal strain) and other parameters of 
left ventricular function, including LVEF and wall 
motion score. Both a poor LVEF and global longitudinal 
strain at presentation were associated with a poor 
echocardiographic outcome (final LVEF <40%). In lupus 
myocarditis patients who presented with a relatively 
preserved LVEF (≥50%), global longitudinal strain, wall 
motion score and diastolic functional parameters were 
Table 3 Echocardiographic findings at diagnosis (initial) and most recent echocardiogram (latest) following treatment for lupus 
myocarditis.
 Initial echocardiogram in lupus 
myocarditis group
Latest echocardiogram in lupus 
myocarditis group
 
 
Total n = 19 Median (IQR)/ratio (%) of test done Median (IQR)/ratio (%) of test done P value
Structural parameter    
LAa diameter (cm) 3.3 (2.8–3.9) 3 (2.5–3.4) 0.088
LVIDb (cm) 5.3 (4.5–5.6) 4.8 (4.0–5.6) 0.106
RVIDc (cm) 3.1 (3.0–3.9) 3 (2.6–3.2) 0.071
Valvular dysfunction (mild/moderate) 10/19 (52.6) MR 5/19 (26.3) MR  
 5/17 (29.4) TR 5/17 (29.4) TR  
Pericardial effusion 6/18 (33.3) small Small 2/18 (11.1)  
 1/18 (5.6) large   
Regional function parameter
RWMA present 17/17 (100) 16/17 (94.1)  
Wall motion scored 1.88 (1.69–2.38) 1.50 (1.31–2.00) 0.017
Global function parameter
MA E′avee (cm/s) 8.0 (6.0–11.0) 8.8 (5.8–10.0) 0.649
MA E/E′f 11.6 (10.0–16.2) 10 (7.75–15.8) 0.281
LVEFg: numerical (%) 35 (32–46) 47 (37–50) 0.023
LVEF: categorical    
≥55% 0/19 (0) 3/19 (15.8)  
45–54% 5/19 (26.3) 10/19 (52.6)  
36–44% 4/19 (21.1) 2/19 (10.5)  
≤35% 10/19 (52.6) 4/19 (21.1)  
TAPSEh (cm) 1.9 (1.6–2.1) 1.7 (1.6–2.0) 0.395
Impaired GLSi 13/13 (100) 13/13 (100)  
GLS(%) −13.0 (−13.5 to −10.3) −15 (−14 to −5) 0.47
aLA diameter: normal ≤3.8 cm; bLVID: normal ≤5.3 cm; cRVID: normal ≤4.2 cm; dWall motion score increased if >1; eMA E′ average: normal <8 cm/s; fMA E/E′: 
normal <8; increased LV filling pressure >15; gLVEF: normal ≥55%; mild impairment: 45–54%; moderate impairment: 36–44%; severe impairment: ≤35%; 
hTAPSE: normal ≥1.6 cm; iGLS: normal −19.7% (95% CI, −20.4 to −18.9%).
E′ave, early diastolic mitral annular velocity, average of lateral and septal measurement; E/E′, ratio of mitral peak velocity of early filling (E) to early 
diastolic mitral annular velocity (E′); GLS, global longitudinal strain; IQR, interquartile range; LA, left atrium; LVEF, left ventricular ejection fraction; LVID, 
left ventricular internal diameter; MA, mitral annular; MR, mitral regurgitation; RVID, right ventricular internal diameter; RWMA, regional wall motion 
abnormalities; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.
Table 4 Initial echocardiographic parameters (at time of 
diagnosis; total n = 19) in patients with a final LVEF <40% 
(poor echocardiographic outcome) compared to those with a 
final LVEF >40%.
 
Parameter at 
diagnosis
Patients with a 
final LVEF <40% 
(n = 5) median (IQR)
Patients with a 
final LVEF ≥40% 
(n = 14) median (IQR)
 
 
P value
MA E′ave 
(cm/s)
11.5 (8.0–12.0) 7.5 (6.5–9.5) 0.221
MA E/E′ 10.0 (9.6–12.9) 13.3 (10.3–16.2) 0.267
LVID (cm) 5.6 (5.4–5.7) 5.2 (4.5–5.5) 0.343
LVEF (%) 34.0 (30–35) 38 (35–50) 0.046
GLS (%) −9.5 (−13 to −9) −13.5 (−16 to −11) 0.095
Wall motion 
score
2.06 (1.88–2.13) 1.81 (1.5–2.19) 0.506 
E′ave, early diastolic mitral annular velocity, average of lateral and septal 
measurement; E/E′, ratio of mitral peak velocity of early filling (E) to early 
diastolic mitral annular velocity (E′); GLS, global longitudinal strain; IQR, 
interquartile range; LVEF, left ventricular ejection fraction; LVID, left 
ventricular internal diameter; MA, mitral annular.
R Du Toit and others Speckle tracking in 
lupus myocarditis
ID: 17-0005; June 2017
DOI: 10.1530/ERP-17-0005
www.echorespract.com 18
significantly impaired compared to a control group. 
The diagnostic role of these parameters as earlier, more 
sensitive markers in clinical lupus myocarditis should be 
defined more clearly through prospective studies. Future 
research is also needed to define the significance of 
echocardiographic evidence of subclinical left ventricular 
dysfunction in asymptomatic SLE patients in comparison 
to clinically evident lupus myocarditis. Such research 
could aid in determining optimal cut-off values for global 
longitudinal strain supporting a diagnosis of clinical 
lupus myocarditis.
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